Video

Panel to discuss new data regarding TP53 mutations and prostate cancer risk

Author(s):

Urology Times staff

“Our case discussion for January 18 is going to be focused on a patient who initially has biochemically recurrent prostate cancer [and] progresses to metastatic disease,” says Veda N. Giri, MD.

In this video, Veda N. Giri, MD, offers a preview of the ENGAGEMENT Study Virtual Genetics Board’s upcoming case discussion focusing on new data on TP53 mutations and prostate cancer risk as well as TP53-related management. which you can sign up for by going to www.prostategenetics.com/engagement. The event will take place on January 18 at 12 pm ET. Giri is a Professor in Medical Oncology and Cancer Biology at Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania.

Related Videos
Daniel Kwon, MD, answers a question during a Zoom video interview
Man talking with doctor | Image Credit: © RFBSIP - stock.adobe.com
Andrew C. Peterson, MD, MPH, answers a question during a Zoom interview
Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
Related Content
Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC
November 26th 2024

Epigenomic cfDNA may accurately assess PSMA expression, Lu-PSMA response in mCRPC

Hannah Clarke
“Our study highlights the potential of epigenomic profiling from a simple blood draw to provide a real-time, non-invasive readout of PSMA expression that corresponds with treatment response," says Jacob E. Berchuck, MD.
Survey sheds light on international genetic testing patterns in prostate cancer
November 18th 2024

Survey sheds light on international genetic testing patterns in prostate cancer

Hannah Clarke
Data demonstrated wide variation in the proportion of patients recommended for testing and showed that barriers to testing remain.
Variants of unknown significance may adversely affect RARP outcomes
November 11th 2024

Variants of unknown significance may adversely affect RARP outcomes

Hannah Clarke
In total, 33.3% of patients with a VUS also had positive lymph node involvement and required adjuvant ADT compared with only 16.2% of patients who did not have a VUS.
Genetic testing in prostate cancer is increasing over time, data suggests
November 11th 2024

Genetic testing in prostate cancer is increasing over time, data suggests

Hannah Clarke
“It is critical that urologists understand when to order germline testing, are comfortable with actually ordering these tests, and integrate medical geneticists when appropriate," says Aditya Bagrodia, MD, FACS.
Genomic risk model validated for prostate cancer risk prediction
November 6th 2024

Genomic risk model validated for prostate cancer risk prediction

Hannah Clarke
Patients with high P-CARE scores had an increased risk of any, metastatic, and fatal prostate cancer compared with patients with median P-CARE scores.
Circulating tumor cell count may serve as a prognostic biomarker in mHSPC
October 8th 2024

Circulating tumor cell count may serve as a prognostic biomarker in mHSPC

Hannah Clarke
Patients with elevated CTC count at baseline experienced poor complete response rates and worsened PFS and OS.
© 2024 MJH Life Sciences

All rights reserved.